Hepatitis C Antiviral Resistance in African-Americans

Completed · Phase 3

Conditions studied: Hepatitis C

In brief

This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.

Key facts

Study ID

NCT00038974

Run by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

People needed

401

Starts

2002-08-01

Expected to finish

2005-11-01

Last updated by the study team

2017-08-03

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California, San Francisco — San Francisco, California, United States
• University of Miami School of Medicine — Miami, Florida, United States
• Rush University — Chicago, Illinois, United States
• University of Maryland School of Medicine — Baltimore, Maryland, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• University of Michigan Medical Center — Ann Arbor, Michigan, United States
• New York-Presbyterian Medical Center — New York, New York, United States
• University of North Carolina — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.